Through Tumor Related Microbial Biomarkers
Micronoma liquid biopsy technology interrogates the microbial signal to detect and predict cancer with clinical-grade accuracy.
Saving patient lives with a minimally-invasive, cancer screening test.
Biotech maven joins early-stage cancer detection company utilizing innovative microbiome analysis SAN DIEGO, Sept. 30, 2020 /PRNewswire/ -- Micronoma, an early stage cancer-detection start-up seeking to develop and commercialize a minimally-invasive, unique...
For Immediate Release Media Contact: Celia Sepulveda, Celia.Sepulveda@Micronoma.com, 858.337.1326 Micronoma Launches with $3 Million Seed Funding First early cancer-detection company to use microbial biomarkers in diagnostics San Diego, Calif....
Humans and Microbes
Humans and microbes co-exist in a mutual beneficial relationship in our bodies. Microbes can be found naturally not only in our stools, but also in our mouths, tissues and even our blood.
The microbiome is the community of all the microbes—bacteria, fungi, protozoa and viruses—that live on and inside the human body.
Microbes and Cancer
Microbes are now known to be found in human tissues, including cancer tissues. Micronoma is going a step further and looking at microbial signatures that would be predictive of a tumor in circulating blood.
Micronoma can detect and distinguish microbes in blood and predict if a patient is cancer free or presenting a specific cancer type.
draw to collect samples
research, discovery, and
NEXT GEN SEQUENCING
Using genomic sequencing to
pipelines to decipher and
New cancer cases
worldwide each year
Cancer deaths each year,
most preventable with
Global liquid biopsy market
forecast for 2023*
Better Approach to Liquid Biopsy
A liquid biopsy is a test done on a sample of blood to look for circulating tumor cells (CTC) or DNA that is shed from the tumor. Liquid biopsies may help find cancer at an early stage.
However, CTCs and ctDNA are scarce, fragile, and heterogenous, which means they are difficult to detect and may be missed. Additionally, they may not be cancer-specific, as various cancers can share many types of alterations.
Traditional liquid biopsies focus on all tumor DNA in the blood to identify the small mutation markers linked to the cancer. Present at often less than 0.1%, ensuring the capture of these rare biomarkers is a difficult task. At Micronoma, we focus on the microbial DNA. With noise and complexity removed, established microbial signatures are enriched and more evident.
Dr. Sandrine Miller
Montgomery Pharm. D. PhD
Founder, Board Member, President and CEO
Founder, Board Member, Chief Analytic Officer, Oncobiota™ Inventor
Rob Knight, PhD
Founder and Advisory Board, Oncobiota™ Inventor
Magda Marquet PhD
Chairman of the Board, Micronoma; Co-Founder, Ajinomoto Althea & AltheaDx and former Chairman of the Board of Directors of UCSD Moores Cancer Center
Goodrich & Rosati
San Diego Angel Conference (SDAC)